The 36-month beta value for FATE is also noteworthy at 2.02. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 12 rating it as “hold,” and 0 rating it as “sell.”
The public float for FATE is 97.84M, and at present, short sellers hold a 11.44% of that float. The average trading volume of FATE on January 23, 2025 was 3.23M shares.
FATE) stock’s latest price update
The stock of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 1.52 when compared to last closing price of 1.32. Despite this, the company has experienced a 6.77% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-03 that SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 2, 2025 the Company granted (i) non-qualified stock options to two newly-hired non-executive employees to purchase a total of 72,000 shares of the Company’s common stock at an exercise price per share of $1.79, which was the closing price per share of the Company’s common stock as reported by NASDAQ on January 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 3,200 shares of its common stock to one newly-hired non-executive employee. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employees being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
FATE’s Market Performance
FATE’s stock has risen by 6.77% in the past week, with a monthly drop of -20.47% and a quarterly drop of -58.51%. The volatility ratio for the week is 6.78% while the volatility levels for the last 30 days are 9.30% for Fate Therapeutics Inc The simple moving average for the past 20 days is -13.24% for FATE’s stock, with a -60.45% simple moving average for the past 200 days.
Analysts’ Opinion of FATE
Piper Sandler, on the other hand, stated in their research note that they expect to see FATE reach a price target of $6, previously predicting the price at $4. The rating they have provided for FATE stocks is “Overweight” according to the report published on June 17th, 2024.
Wells Fargo gave a rating of “Equal Weight” to FATE, setting the target price at $6 in the report published on March 27th of the previous year.
FATE Trading at -33.58% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.82% of loss for the given period.
Volatility was left at 9.30%, however, over the last 30 days, the volatility rate increased by 6.78%, as shares sank -19.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.97% lower at present.
During the last 5 trading sessions, FATE rose by +6.77%, which changed the moving average for the period of 200-days by -80.77% in comparison to the 20-day moving average, which settled at $1.5445. In addition, Fate Therapeutics Inc saw -18.79% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FATE starting from Bressi Jerome Charles, who sale 5,980 shares at the price of $1.55 back on Jan 10 ’25. After this action, Bressi Jerome Charles now owns 270,203 shares of Fate Therapeutics Inc, valued at $9,269 using the latest closing price.
TAHL CINDY, the of Fate Therapeutics Inc, sale 5,654 shares at $1.55 during a trade that took place back on Jan 10 ’25, which means that TAHL CINDY is holding 336,707 shares at $8,764 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -14.62 for the present operating margin
- -2.3 for the gross margin
The net margin for Fate Therapeutics Inc stands at -13.25. The total capital return value is set at -0.43. Equity return is now at value -46.59, with -34.32 for asset returns.
Based on Fate Therapeutics Inc (FATE), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.33. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -20.25.
Currently, EBITDA for the company is -172.23 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 15.89. The receivables turnover for the company is 3.26for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.29.
Conclusion
In summary, Fate Therapeutics Inc (FATE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
